A randomized double‐blind, placebo‐controlled clinical phase IIa trial on safety, immunomodulatory effects and pharmacokinetics of EA‐230 during experimental human endotoxaemia

AIMS: EA‐230 is a human chorionic gonadotropin hormone‐derived linear tetrapeptide, developed for the treatment of systemic inflammation‐related disorders. EA‐230 has shown promising immunomodulatory and tissue‐protective effects in animals and an excellent safety profile in human phase I studies th...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Clin Pharmacol
Auteurs principaux: van Groenendael, Roger, Kox, Matthijs, Leijte, Guus, Koeneman, Bouke, Gerretsen, Jelle, van Eijk, Lucas, Pickkers, Peter
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6595370/
https://ncbi.nlm.nih.gov/pubmed/30919998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13941
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires